Division of Respiratory Medicine, Mito Kyodo General Hospital-Mito Medical Center, University of Tsukuba, Mito, Japan.
Divisions of Respiratory Medicine and Thoracic Surgery, Mito Medical Center, Mito, Japan.
Anticancer Res. 2020 Feb;40(2):957-964. doi: 10.21873/anticanres.14029.
BACKGROUND/AIM: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation.
We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people.
There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment.
By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.
背景/目的：描述使用系统疗法治疗具有间变性淋巴瘤激酶（ALK）融合基因突变的非小细胞肺癌（NSCLC）患者的真实临床结果。
我们对 2008 年 4 月至 2019 年 3 月来自覆盖 300 万人的 16 家医疗机构的病历进行了回顾性图表审查。
共有 129 例 ALK 重排 NSCLC 患者。其中，103 例患者（包括 40 例复发性疾病患者）接受了 ALK-酪氨酸激酶抑制剂（TKI）和化疗。我们的治疗结果与先前报道的临床试验和临床实践研究相当。一线阿来替尼、ALK-TKI 治疗顺序和培美曲塞联合化疗有助于治疗结果。
通过安排治疗顺序，如 ALK-TKI 治疗顺序和化疗方案，即使在真实的临床实践中，也有可能获得几乎等同于临床试验的治疗结果。
